Discovery of SIPI6473, a New, Potent, and Orally Bioavailable Multikinase Inhibitor for the Treatment of Non-small Cell Lung Cancer

Discovery of SIPI6473, a New, Potent, and Orally Bioavailable Multikinase Inhibitor for the Treatment of Non-small Cell Lung Cancer

Abstract A novel series of quinazoline derivatives were designed, synthesized, and evaluated as multikinase inhibitors. Most of these compounds showed antiproliferation activities of several human cancer cell lines and exhibited inhibition efficacy against the estimated glomerular filtration rate (E...

Full description

Bibliographic Details
Main Authors:	Xiu Gu, Zi-Xue Zhang, Min-Ru Jiao, Xin-Yan Peng, Jian-Qi Li, Qing-Wei Zhang
Format:	Article
Language:	English
Published:	Georg Thieme Verlag KG 2021-03-01
Series:	Pharmaceutical Fronts
Subjects:	sipi6473 multikinase inhibitor antitumor non-small cell lung cancer
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1731081

Similar Items

Lu sipi, a Marker of Tongan Distinction
by: Toloke, Elizabeth Na'asipa
Published: (2021)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
by: Anna Strasma, et al.
Published: (2021-03-01)

Study on Biopharmaceutics Classification and Oral Bioavailability of a Novel Multikinase Inhibitor NCE for Cancer Therapy
by: Yang Yang, et al.
Published: (2014-04-01)

Rare complications of multikinase inhibitor treatment
by: Fabián Pitoia, et al.

Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized TherapySummary
by: Daniel Q. Huang, et al.
Published: (2021-01-01)

Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01)

SUMPAH PEGAWAI NEGERI SIPIL DALAM PERSPEKTIF HUKUM ISLAM
by: Hamka Siregar
Published: (2017-02-01)

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
by: Dieter Zopf, et al.
Published: (2016-11-01)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
by: Tiziana Feola, et al.
Published: (2021-07-01)

A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC
by: Justin F. Gainor, MD, et al.
Published: (2020-09-01)

The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer
by: P O Rumyantsev
Published: (2015-06-01)

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
by: Carla Fernanda Nava, et al.
Published: (2019-10-01)

Measurements of Young's Modulus on Rock Samples at Small Amplitude and Low Frequency : RockHard Deformations
by: Fintland, Trygve Westlye
Published: (2011)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
by: Nanna Bæk Møller, et al.
Published: (2019-09-01)

Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
by: Changhoon Yoo, et al.
Published: (2021-03-01)

Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
by: Songporn Oranratnachai, et al.
Published: (2021-03-01)

Specificity of hand-foot skin reaction induced by multikinase inhibitors: clinical, histological and ultrasound characteristics
by: E. A. Shatokhina, et al.
Published: (2020-07-01)

Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas
by: Asmus, E., et al.
Published: (2022)

Successful Treatment with Pazopanib for Multiple Lung Metastases of Inguinal Epithelioid Sarcoma: A Case Report
by: Sanae Irimura, et al.
Published: (2015-09-01)

Discovery of N-(2-Aminophenyl)-4-(bis(2-chloroethyl)amino)Benzamide as a Potent Histone Deacetylase Inhibitor
by: Lihui Zhang, et al.
Published: (2019-08-01)

The use of regorafenib in patients with disseminated gastrointestinal stromal tumours. A review of the literature. A clinical case
by: D. A. Filonenko, et al.
Published: (2018-07-01)

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
by: Sofie Mohlin, et al.
Published: (2019-08-01)

Contribution à une nouvelle voie de signalisation de l'InsP5/InsP6 via la caractérisation de l'inositol phosphate multikinase
by: Leyman, Alexandre
Published: (2011)

Les universités indiennes (« Tribal colleges ») aux États-Unis : choix de société et intégration
by: Susanne BERTHIER-FOGLAR
Published: (2015-12-01)

REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE
by: P. O. Rumyantsev
Published: (2015-04-01)

Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?
by: Goel G
Published: (2018-03-01)

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials
by: Yin X, et al.
Published: (2018-10-01)

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study
by: Thomas Brodowicz, et al.
Published: (2020-12-01)

Sorafenib-Induced Cutaneous Toxicities: Four Different Presentations
by: Pooja Bains, et al.
Published: (2019-01-01)

AFP-producing hepatoid adenocarcinoma (HAC) of peritoneum and omentum: a case report and literature review
by: Zou M, et al.
Published: (2019-09-01)

Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma
by: Kehua Zhou, et al.
Published: (2019-06-01)

Beyond Bevacizumab: an outlook to new antiangiogenics for the treatment of ovarian cancer
by: Sven eMahner, et al.
Published: (2015-10-01)

Discovery of N-(2-Amino-4-Fluorophenyl)-4-[bis-(2-Chloroethyl)-Amino]-Benzamide as a Potent HDAC3 Inhibitor
by: Yiming Chen, et al.
Published: (2020-10-01)

THE USE OF SORAFENIB (NEXAVAR) IN TREATMENT OF PATIENT WITH DISSEMINATED PARATHYROID CANCER: A CASE REPORT
by: V. A. Gorbunova, et al.
Published: (2017-04-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

Phototoxic Reaction Induced by Pazopanib
by: Siriorn Udompanich, et al.
Published: (2018-11-01)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
by: Nicola Personeni, et al.
Published: (2018-06-01)

Discovery and antitumor evaluation of novel inhibitors of spermine oxidase
by: Lidan Sun, et al.
Published: (2019-01-01)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
by: Walid Shalata, et al.
Published: (2021-07-01)

Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials
by: Pierre-Yves Cren, et al.
Published: (2020-11-01)